Citi Starts Dicerna Pharmaceuticals (DRNA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Dicerna Pharmaceuticals (DRNA) PT Lowered to $20 at H.C. Wainwright on Dilution
September 13, 2018 7:16 AM EDTH.C. Wainwright analyst Ed Arce lowered the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $21.00) while maintaining a Buy rating, citing dilution.
Arce commented, "Last week, as we expected, Dicerna announced positive initial 6-week data (Day 43) in which most (5 of 8) assessed PH patients in Group B of... More
